<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479180</url>
  </required_header>
  <id_info>
    <org_study_id>PVS-06-003/06-004</org_study_id>
    <nct_id>NCT00479180</nct_id>
  </id_info>
  <brief_title>Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use</brief_title>
  <official_title>Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pervasis Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pervasis Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascugel™ is safe when placed at the anastomotic site at the time of surgery during creation
      of an AV graft or fistula for hemodialysis access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, parallel group, Phase I/II clinical trial of Vascugel™ treatment
      vs. Gelfoam® in patients undergoing creation of an arteriovenous graft or fistula for
      hemodialysis access.

      All patients will undergo preoperative duplex ultrasound imaging and/or angiography (whatever
      is the standard of care at the research site) of the vein and artery to evaluate the optimal
      site for vascular access placement in the upper extremity.

      Patients will be examined with Doppler ultrasound or standard of care immediately after
      surgery to verify patency of the AV graft or fistula.

      During the follow-up period, each patient will undergo a physical examination and imaging of
      the vascular access at specified intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of vascugel</measure>
    <time_frame>6 months followed by 2.5 year extension</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Hemodialysis Access</condition>
  <arm_group>
    <arm_group_label>AVG1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascugel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVG2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelfoam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVF3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascugel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVF4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelfoam</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vascugel</intervention_name>
    <description>One time implant on the day of surgery</description>
    <arm_group_label>AVG1</arm_group_label>
    <arm_group_label>AVF3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>One time implant on the day of surgery</description>
    <arm_group_label>AVG2</arm_group_label>
    <arm_group_label>AVF4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female patients (ages of 18 to 89, inclusive) who are undergoing
             placement of an AV graft or fistula for hemodialysis access

        Exclusion Criteria:

          -  Patient is currently on an active transplant list for a kidney from a deceased donor
             OR is undergoing assessment and expects to be placed on the active transplant list
             within the next twenty-four weeks OR expects to receive a living donor kidney within
             twenty-four weeks.

          -  Patient is expecting another solid organ transplant or a bone marrow transplant.

          -  Patient has had more than one access surgery (defined as a new access, not a revision)
             in the target limb.

          -  Patient is currently on chronic, systemic immunosuppressant medication other than
             locally or topically applied steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Elizabeth Merica, Director,Clinical Affairs</name_title>
    <organization>Pervasis Therapeutics</organization>
  </responsible_party>
  <keyword>Hemodialysis access</keyword>
  <keyword>Arteriovenous graft</keyword>
  <keyword>Arteriovenous fistula</keyword>
  <keyword>End stage renal disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

